Edgewise Therapeutics, Inc. (EWTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US28036F1057
Edgewise Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -191.41 m USD |
| EBIT | -167.79 m USD |
| Net income | -167.80 m USD |
| Diluted EPS – continuing operations | -1.63 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
More stocks
- FTI CONSULTING, INC (FCN)
- FIRST FINANCIAL BANKSHARES INC (FFIN)
- Mazda Motor Corp (7261.T)
- Bridgepoint Group PLC (BPT.L)
- PATTERSON UTI ENERGY INC (PTEN)
- Mondi PLC (MNDI.L)
- Tauron Polska Energia SA (TPE.WA)
- Ramelius Resources Ltd (RMS.AX)
- Zhejiang Huazheng New Material (603186.SS)
- Henan Pinggao Electric Co Ltd (600312.SS)
- FEDERATED HERMES, INC. (FHI)
- Champion Homes, Inc. (SKY)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.